A potent 5-hydroxytryptamine receptor (5-HT(2A)) antagonist, DV-7028, delays arterial thrombosis development in rats

Thrombosis Research

Volumn 90, Issue 6, 1998, Pages 259-270

  Pawlak, Dariusz ^a   Pawlak, Krystyna ^a   Chabielska, Ewa ^a   Malyszko, Jolanta ^a   Takada, Akikazu ^b   Myśliwiec, Michal ^a   Buczko, Wlodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT(2A) receptor; Arterial and venous thrombosis; DV 7028

Indexed keywords

3 [2 [4 (4 FLUOROBENZOYL)PIPERIDIN 1 YL]ETHYL] 6,7,8,9 TETRAHYDRO 2H PYRIDO[1,2 A] 1,3,5 TRIAZINE 2,4(3H) DIONE; ANTICOAGULANT AGENT; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; DOSE RESPONSE; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

ANIMALS; AORTA, ABDOMINAL; BLEEDING TIME; KETANSERIN; MALE; PIPERIDINES; PLATELET AGGREGATION; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS; THROMBOPHLEBITIS; THROMBOSIS; TRIAZINES;

EID: 0032526822     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00037-1     Document Type: Article

References (43)

1. De Clerck F., Herman A.G. 5-hydroxytryptamine and platelet aggregation. Fed Proc. 42:1983;228-232.
2. 2 receptor antagonist. Agents Actions. 12:1982;388-397.
3. Dabire H., Cherqui C., Safar M., Shmit H. Haemodynamics aspects of serotonin. Clin Physiol Biochem. 8:1990;56-63.
4. 2 receptor antagonist, on ischemic cerebral blood flow and infarct volume in rat middle cerebral artery occlusion. Stroke. 25:1994;481-486.
5. Frishman W.H., Huberfeld S., Okin S., Wang Y.H., Kumar A., Shareef B. Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. J Clin Pharmacol. 35:1995;541-572.
6. Verstraete M. Prevention of atherosclerotic complications with ketanserin. Br Med J. 298:1989;424-429.
7. Fozard R.F. Mechanism of hypotensive effect of ketanserin. J Cardiovasc Pharmacol. 4:1982;829-838.
8. Shibano T., Tanaka T., Morishima Y., Yasuoka M., Watanabe K., Fujii F. Pharmacological profile of a new 5-hydroxytryptamine 2 receptor antagonist, DV-7028. Arch Int Pharmacodyn Ther. 319:1992;114-128.
9. Hornsta G., Vandelmans-Starrengurg A. Introduction of experimental arterial occlusive thrombi in rats. Atherosclerosis. 17:1973;369-382.
10. Reyers I., Mussoni L., Donati M.B., de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res. 18:1980;669-674.
11. Dejana E., Villa S., De Gaetano G. Bleeding time in rats. A comparison of different experimental conditions Thromb Haemost. 48:1991;108-111.
12. 1 on human platelet aggregation in whole blood in vitro. J Pharm Pharmacol. 37:1985;139-141.
13. Born G.V., Cross M.J. The aggregation of blood platelets. J Physiol. 168:1963;178-195.
14. Koutouzov S., Cothenet-Vernoux L., Marche P., Dausse J.P. Influence of alpha- and beta-adrenoceptors on thrombin-induced serotonin release in rat platelets. Thromb Res. 40:1985;147-159.
15. Nicholas T. A perfused tail artery preparation from the rat. J Pharm Pharmacol. 21:1969;826-832.
16. Van Rossum J.M., Hurkman J.A., Wolters C.J.J. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn Ther. 143:1963;299-331.
17. 50) of an enzymatic reaction. Biochem Pharmacol. 22:1973;3099-3108.
18. Harker L.A., Ritchie J.L. The role of platelets in acute vascular events. Circulation. 62:1980;V13-V19.
19. Vermylen J., Verstraete M., Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol. 8:1986;2B-9B.
20. 2-adrenergic and serotonergic antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res. 55:1984;642-652.
21. Bush L.R. Effect of the serotonin antagonists, cyproheptadine, ketanserin and mianserin, on cyclic flow reductions in stenosed canine coronary arteries. J Pharmacol Exp Ther. 240:1987;674-682.
22. Aiken J.W., Goram R.R., Shebusli R.J. Prevention of blockade of partially obstructed coronary arteries with prostacyclin correlated with inhibition of platelet aggregation. Prostaglandins. 17:1979;483-494.
23. Folts J.D., Gallagher K.B., Rowe G.G. Blood flow reduction in stenosed canine coronary arteries. Vasospasm or platelet aggregation? Circulation. 65:1982;248-254.
24. Bush L.R., Campbell W.B., Buja L.M., Tilton G.F., Willerson J.T. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 69:1984;1161-1170.
25. Aiken J.W. Pharmacological analysis of factors influencing platelet aggregation in stenosed coronary arteries of dogs. Ann N Y Acad Sci. 454:1985;131-134.
26. Golino P., Buja L.M., Ashton J.H., Kulkarini P., Taylor A., Willerson J.T. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation. 78:1988;701-711.
27. Golino P., Ashton J.H., Buja L.M., Rosolowsky M., Taylor A.L., Mc Natt J., Campbell W.B., Willerson J.T. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Circulation. 79:1989;154-166.
28. Hirsh J, Brai EA. Pathogenesis of thrombosis. In: Haemostasis & Thrombosis. A conceptual approach. New York: Churchill Livingstone Inc., 1983. pp. 92-109.
29. Martin M. Formation of thrombus and thrombolysis in animal experiments. Angiologica. 5:1968;80-94.
30. Hara H., Kitajima A., Shimada H., Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost. 66:1991;484-488.
31. Bernat A., Vallée E., Maffrand J.P., Roncucci R. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis. Thromb Res. 37:1985;279-285.
32. Bernat A., Vallee E., Maffrand J.P., Gordon J.L. The role of platelets and in ADP experimental thrombosis induced by venous stasis in the rat. Thromb Res. 52:1988;65-70.
33. De Clerck F., Xhonneux B. Effect of ketanserin a selective 5-hydroxytryptamine-2 serotonergic antagonist on the secondary recruitment of human platelets in vitro. Agents Actions. 17:1986;515-526.
34. Anderson G.M., Hall L.M., Horne W.C., Yang J.X. Adenosine diphosphate inhibits the serotonin transporter. Biochim Biophys Acta. 1283:1996;14-20.
35. Bevan J., Heptinstall S. Effect of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets. Thromb Res. 30:1983;415-423.
36. Mills D.C.B., Roberts G.C.K. Membrane active drugs and the aggregation of human platelets. Nature. 213:1967;35-38.
37. Laubscher A., Pletscher A. Shape change and uptake of 5-hydroxytryptamine in human blood platelets. Life Sci. 24:1979;1833-1840.
38. Pott J.W.R., Moreland R.S., Gantzos R.D., Babcock C., Bohr D.F. Vascular interactions of serotonin and norepinephrine in renal hypertensive rabbits. J Hypertens. 4:1986;207-213.
39. 2-serotonergic receptor antagonist. Thromb Haemost. 65:1991;415-420.
40. 2 receptor system. J Pharmacol Exp Ther. 245:1988;1010-1015.
41. Buczko W., Gambino M.C., De Gaetano G. Prolongation of the tail bleeding time by ketanserin. mechanism of action Eur J Pharmacol. 103:1984;261-268.
42. De Clerck F., Somers Y., Van Grop L. Platelet wall interactions in hemostasis. Implication of 5-hydroxytryptamine Agents Actions. 15:1984;627-637.
43. De Clerck F., Van Nueten J.M. Platelet-mediated vascular contractions. Inhibition of the serotonergic component by ketanserin Thromb Res. 27:1982;713-727.